Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1tablet and Harnal-D - Tablet in BPH Patients With LUTS

Inclusion Criteria: * Over 50 years old, BPH diagnosted, Adult Male Subject * IPSS ≥ 13 point * PSA \< 4ng/mL * 5ml/sec \< Qmax ≤ 15ml/sec Exclusion Criteria: * Prostatic cancer * 250ml \< PVR * ALT or AST \> 2 times (Upper Normal Range) * Total Bilirubin \> 1.5 times (Upper Normal Range) * Treated with α-adrenalin receptor blocker within 2weeks before screening * Treated with 5Alpha-Reductase Inhibitor within 6 months before screening * Treated with phytotherapy within 2weeks before screening * Treated with Anabolic Steroid within 6 months before screening